Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biontech Se ADR
(NQ:
BNTX
)
92.06
+1.93 (+2.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biontech Se ADR
< Previous
1
2
3
4
5
6
7
8
9
...
53
54
Next >
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Today 5:01 EDT
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For BioNTech
May 07, 2024
Via
Benzinga
BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript
May 06, 2024
BNTX earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q1 2024
May 06, 2024
BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
What's Going With BioNTech Stock On Monday?
May 06, 2024
BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by innovative R&D and strong cash reserves.
Via
Benzinga
Assessing BioNTech: Insights From 11 Financial Analysts
April 17, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For BioNTech
March 21, 2024
Via
Benzinga
Earnings Outlook For BioNTech
March 19, 2024
Via
Benzinga
BioNTech Slides After Reporting Losses As Covid Vaccine Sales Take A Hit
May 06, 2024
BioNTech missed the Street's sales views and reported wider-than-expected losses.
Via
Investor's Business Daily
Exposures
COVID-19
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
May 06, 2024
Via
Benzinga
Wall Street Looks To Extend Rally Amid Caution Over Fed Speeches, More Earnings: Why This Analyst Thinks Bull Market Is Still 'Quite Young'
May 06, 2024
U.S. stocks are likely to extend their gains as major index futures are modestly higher on Monday. Strong earnings reports continue to support the market, with S&P 500 earnings expected to grow by 5%...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
May 01, 2024
Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix....
Via
Benzinga
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
May 06, 2024
According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
April 26, 2024
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
What's Going On With Pfizer Stock On Thursday?
April 25, 2024
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S.
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
April 23, 2024
Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams.
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
April 12, 2024
Via
Benzinga
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
April 09, 2024
These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around.
Via
InvestorPlace
CureVac, GS Partner Release Data On Influenza Vaccine Study
April 04, 2024
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A...
Via
Benzinga
The 3 Best Bargain Stocks to Buy in Q2 2024
March 31, 2024
For those who don’t want to chase what everyone else is acquiring, these are intriguing ideas for best bargain stocks to buy.
Via
InvestorPlace
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
March 26, 2024
These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.
Via
InvestorPlace
BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript
March 20, 2024
BNTX earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 20, 2024
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and...
Via
Benzinga
BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials
March 20, 2024
BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer Inc (NYSE: PFE) for saving the world from the pandemic with their jointly developed vaccine.
Via
Benzinga
Exposures
COVID-19
Stocks Quietly Higher As Central Bank Wraps Up Meeting
March 20, 2024
Stocks are cautiously higher ahead of the conclusion of the central bank's policy meeting.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q4 2023
March 20, 2024
BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
BioNTech Tumbles As Fourth-Quarter Sales Dive 65% And Miss Forecasts
March 20, 2024
BioNTech also reported plummeting earnings that missed forecasts and issued light 2024 guidance.
Via
Investor's Business Daily
Why Is BioNTech Stock Trading Lower On Wednesday?
March 20, 2024
BioNTech reported Q4 2023 earnings below expectations, with EPS at €1.90 vs. €9.26 last year. Sales were €1.479 billion, missing consensus. Guidance for 2024 anticipates revenues of €2.5-€3.1 billion,...
Via
Benzinga
US Stock Futures Stall As Traders Await Fed Chair Powell's Decision; Analyst Sees S&P 500 Showing 'Signs Of Near-Term Top'
March 20, 2024
Investors remain cautious ahead of the Federal Reserve‘s interest rate decision, with stock futures on Wednesday hinting at a lower opening.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Earnings Scheduled For March 20, 2024
March 20, 2024
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
53
54
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.